Literature DB >> 11196194

Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.

A Mazumdar1, L Adam, D Boyd, R Kumar.   

Abstract

Heregulin-beta1, which binds human epidermal growth factor receptors 3 and 4, promotes motility and invasiveness of breast cancer cells. Considering the established role of urokinase plasminogen activator (uPA) and its receptor (uPAR) in invasion, this study was undertaken to explore the role of heregulin-beta1 in regulating uPA and uPAR in breast cancer invasion. The stimulation by heregulin-beta1 of noninvasive human breast cancer MCF-7 cells induced the expression of uPA mRNA, protein, and its plasminogenic activity. This uPA mRNA expression was blocked by a transcriptional inhibitor, actinomycin D, and does require de novo protein synthesis for its optimal induction in MCF-7 cells, but not in mouse mammary epithelial HC11 cells. Heregulin-beta1 also induced the expression of uPAR mRNA and protein in an actinomycin D-sensitive manner and cycloheximide superinduced the uPAR mRNA. Heregulin-beta1-stimulated signaling initiated the transcription from uPA- and uPAR-promoters. These results suggest that heregulin-beta1 regulation of breast cancer cell invasion may be mediated in part through the up-regulation of uPA and uPAR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196194

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

2.  Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth.

Authors:  Padmamalini Kannan-Thulasiraman; Darcie D Seachrist; Ganapati H Mahabeleshwar; Mukesh K Jain; Noa Noy
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

3.  Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.

Authors:  Sumaira Amir; Naira V Margaryan; Valerie Odero-Marah; Zhila Khalkhali-Ellis; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2005-04-21       Impact factor: 4.742

Review 4.  The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.

Authors:  S A Eccles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Impaired MicroRNA Processing Facilitates Breast Cancer Cell Invasion by Upregulating Urokinase-Type Plasminogen Activator Expression.

Authors:  Hyangsoon Noh; Sungguan Hong; Zheng Dong; Zhixing K Pan; Qing Jing; Shuang Huang
Journal:  Genes Cancer       Date:  2011-02

Review 6.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers.

Authors:  Maria José Oliveira; Tineke Lauwaet; Georges De Bruyne; Marc Mareel; Ancy Leroy
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-08       Impact factor: 4.553

8.  An isoform of C/EBPβ, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration.

Authors:  Bae-Hang Park; Sungho Kook; SeanBong Lee; Jong-Hyeon Jeong; Adam Brufsky; Byeong-Chel Lee
Journal:  J Biol Chem       Date:  2013-08-21       Impact factor: 5.157

9.  C4.4A as a candidate marker in the diagnosis of colorectal cancer.

Authors:  C Paret; D Hildebrand; J Weitz; A Kopp-Schneider; A Kuhn; A Beer; R Hautmann; M Zöller
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

10.  Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression.

Authors:  Q Hu; Y-Y Lu; H Noh; S Hong; Z Dong; H-F Ding; S-B Su; S Huang
Journal:  Oncogene       Date:  2012-09-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.